News Contact Us

Iterum to conduct trials for oral Sulopenem in uncomplicated UTIs

Author : Ojaswita Kutepatil | Published Date : 2018-08-11 

Pharmaceutical giant Iterum Therapeutics plc, which develops medications for infections caused by multi-drug resistance pathogens, has recently announced its clinical trial for Sulopenem. Sources state that this would mark the first phase of its Phase 3 clinical trials.

For the uninitiated, Sulopenem works well during in-vitro activity to fight organisms commonly concerned with urinary tract and intra-abdominal infections. According to reliable sources, in the trial known as Sulopenem for Resistant Enterobacteriaceae (Sure) 1, the oral sulopenem will be compared to oral ciprofloxacin in women down with uncomplicated urinary tract infections (uUTI).

Sulopenem is Iterum’s lead compound and new antibiotic meant to cure gram-negative and multi-drug resistant infections. 

As per a news release by Iterum, patients infected with quinolone resistant pathogen may need secondary antibiotic prescription or hospitalization, if quinolone is prescribed for uncomplicated UTI. Among U. S patients, resistance to fluoroquinolone has been observed in over 20% of isolates from urinary tract caused primarily by resistance to E. coli and P.mirabilis.

The growth of UTIs with multi-drug resistance is disturbing and current drugs fail in treatment, claimed Iterum’s M.D. and Chief Scientific Officer, Michael Dunne. Resistance to fluoroquinolones is rising and healthcare professionals urgently need new oral options to treat infections such as UTIs, he further added.

FDA has warned about the usage of fluoroquinolones for uUTI patients who can be prescribed other drugs as well, as it poses more risks than benefits, stated Dunne.

Approximately 1,364 patients are expected to enroll for the study conducted under an agreement of Special Protocol Assessment (SPA) from the FDA. The trial process will be carried out with patients receiving either oral sulopenem twice for five days or oral ciprofloxacin twice for three days, the ideal uUTI dosage.

Incidentally, Iterum is in talks for initiating two additional Phase 3 clinical trials that will examine the use of oral and intravenous sulopenem in complicated UTIs and complicated intra abominable infections, reported sources familiar with the trials.

About Author

Ojaswita Kutepatil

Ojaswita Kutepatil

Equipped with an ardent interest in writing, Ojaswita Kutepatil, a content developer by profession, presently writes articles for fractovia.org and a couple of other portals. When she isn’t harnessing the power of the pen, she loves to pursue her hobbies of cooking, reading, and crafting, to name a few. She can be contacted at- [email protected] | https://twitter.com/ojaswita_k

Related News

Go-Jek secures additional $100M in funds from Astra International

Published Date: 2019-03-05         Author: Ojaswita Kutepatil

Go-Jek, the Indonesian ride-hailing & logistics startup, is currently in the news for raising another $100 million in its ongoing Series F investment round, with the help of which the company aims to secure at least $2 billion in the long run. As per trusted sources, the latest cash influx co... Read More

Adaptive3D secures financing from latest Series A investment round

Published Date: 2019-02-06         Author: Ojaswita Kutepatil

Applied Ventures LLC and DSM Venturing led the Series A investment round.   The investment round also saw participation from Chemence & current investors that were led by late Margaret McDermott & Mary McDermott Cook. Adaptive3D Technologies (Adaptive3D), an American additiv... Read More

Uber Eats to pilot Coles’ ready-to-eat meals in a new partnership deal

Published Date: 2019-01-29         Author: Ojaswita Kutepatil

The supermarket giant Coles has teamed up with Uber Eats to test-launch meal delivery services across Australia Uber Eats, an American online food delivery platform, and Australian supermarket chain Coles, have reportedly signed a partnership agreement for meal delivery to customers. Under the pa... Read More

© 2020 Fractovia. All Rights Reserved